Evelin Elfriede Balbino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Evelin Elfriede Balbino has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Armando Fartolino Guerrero
Harvard TH Chan School of Public Health Harvard University Boston, MA United States
2 shared publications - Clara Krystal Pérez Fermin
Harvard TH Chan School of Public Health Harvard University Boston, MA United States
2 shared publications - Danielle Argentina Silva
Harvard TH Chan School of Public Health Harvard University Boston, MA United States
2 shared publications - Janis L. Breeze
Tufts Medical Center, Boston, MA
2 shared publications - Nathalie Monique Vandevelde
Sciensano
2 shared publications - Paola Gonzalez-Mego
Neuromodulation Center and Center for Clinical Research Learning, Harvard Medical School, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Boston, USA
2 shared publications
Latest Publications
- Open Access
- 9 August 2018
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 7 (8) , e10516
The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial
Background: End-stage renal disease (ESRD) is the last stage of chronic kidney disease, mainly caused by type 2 diabetes mellitus and characterized by an increased mortality risk related to cardiovascular disease. Low-dose aspirin (acetylsalicylic acid or ASA) seems to effectively prevent cardiovascular events in patients with ESRD. However, the number of interventional studies in this population remains limited and the mechanisms of aspirin-related bleeding remain poorly understood. Aspirin’s efficacy and safety may be modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. Objective: The overall objective of this protocol is to (1) evaluate aspirin’s safety and efficacy in reducing the risk of thrombotic events in patients with ESRD on hemodialysis and (2) examine whether aspirin’s efficacy is modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. Specifically, the primary objective is to compare the 12-month rate of any thrombotic event (cardiac death, nonfatal myocardial infarction, nonfatal stroke, arteriovenous fistula thrombosis) and Thrombolysis in Myocardial Infarction (TIMI) major bleeding in patients treated with aspirin compared to those on placebo. Secondary objectives are to test for effect modification of treatment by the presence of type 2 diabetes mellitus or platelet hyperreactivity and compare the rate of TIMI minor bleeding between treatment groups. Methods: We developed a protocol for a phase 2 randomized, single-center, placebo-controlled, triple-blind, superiority clinical trial to assess the prophylactic efficacy and safety of aspirin in patients with ESRD and on hemodialysis. It follows the ethical principles of the Declaration of Helsinki of the World Medical Association. A total of 342 participants would be enrolled over 12 months at a large dialysis center. Patients will be randomized in a 1:1 ratio and stratified by presence of type 2 diabetes mellitus and platelet hyperreactivity to receive either oral aspirin (100 mg/d) or placebo for a treatment period of 12 months. An intention-to-treat statistical analysis will be performed. Results: The randomized clinical trial will be performed after approval by the ethical committee of the participating center and registration at ClinicalTrials.gov. Conclusions: We provide a protocol for a randomized controlled trial to evaluate the safety and efficacy of treatment with aspirin to reduce the risk of thrombotic events. In addition, such a study would further our understanding of the mechanism of aspirin-related bleeding and help identify subgroups of best-responders and patients with a higher risk of adverse events. Registered Report Identifier: RR1-10.2196/10516
- 9 August 2018
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 7 (8) , e10516
Open AccessThe Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial
Background: End-stage renal disease (ESRD) is the last stage of chronic kidney disease, mainly caused by type 2 diabetes mellitus and characterized by an increased mortality risk related to cardiovascular disease. Low-dose aspirin (acetylsalicylic acid or ASA) seems to effectively prevent cardiovascular events in patients with ESRD. However, the number of interventional studies in this population remains limited and the mechanisms of aspirin-related bleeding remain poorly understood. Aspirin’s efficacy and safety may be modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. Objective: The overall objective of this protocol is to (1) evaluate aspirin’s safety and efficacy in reducing the risk of thrombotic events in patients with ESRD on hemodialysis and (2) examine whether aspirin’s efficacy is modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. Specifically, the primary objective is to compare the 12-month rate of any thrombotic event (cardiac death, nonfatal myocardial infarction, nonfatal stroke, arteriovenous fistula thrombosis) and Thrombolysis in Myocardial Infarction (TIMI) major bleeding in patients treated with aspirin compared to those on placebo. Secondary objectives are to test for effect modification of treatment by the presence of type 2 diabetes mellitus or platelet hyperreactivity and compare the rate of TIMI minor bleeding between treatment groups. Methods: We developed a protocol for a phase 2 randomized, single-center, placebo-controlled, triple-blind, superiority clinical trial to assess the prophylactic efficacy and safety of aspirin in patients with ESRD and on hemodialysis. It follows the ethical principles of the Declaration of Helsinki of the World Medical Association. A total of 342 participants would be enrolled over 12 months at a large dialysis center. Patients will be randomized in a 1:1 ratio and stratified by presence of type 2 diabetes mellitus and platelet hyperreactivity to receive either oral aspirin (100 mg/d) or placebo for a treatment period of 12 months. An intention-to-treat statistical analysis will be performed. Results: The randomized clinical trial will be performed after approval by the ethical committee of the participating center and registration at ClinicalTrials.gov. Conclusions: We provide a protocol for a randomized controlled trial to evaluate the safety and efficacy of treatment with aspirin to reduce the risk of thrombotic events. In addition, such a study would further our understanding of the mechanism of aspirin-related bleeding and help identify subgroups of best-responders and patients with a higher risk of adverse events. Registered Report Identifier: RR1-10.2196/10516
- Open Access
- 28 March 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND End-stage renal disease (ESRD) is the last stage of chronic kidney disease, mainly caused by type 2 diabetes mellitus and characterized by an increased mortality risk related to cardiovascular disease. Low-dose aspirin (acetylsalicylic acid or ASA) seems to effectively prevent cardiovascular events in patients with ESRD. However, the number of interventional studies in this population remains limited and the mechanisms of aspirin-related bleeding remain poorly understood. Aspirin’s efficacy and safety may be modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. OBJECTIVE The overall objective of this protocol is to (1) evaluate aspirin’s safety and efficacy in reducing the risk of thrombotic events in patients with ESRD on hemodialysis and (2) examine whether aspirin’s efficacy is modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. Specifically, the primary objective is to compare the 12-month rate of any thrombotic event (cardiac death, nonfatal myocardial infarction, nonfatal stroke, arteriovenous fistula thrombosis) and Thrombolysis in Myocardial Infarction (TIMI) major bleeding in patients treated with aspirin compared to those on placebo. Secondary objectives are to test for effect modification of treatment by the presence of type 2 diabetes mellitus or platelet hyperreactivity and compare the rate of TIMI minor bleeding between treatment groups. METHODS We developed a protocol for a phase 2 randomized, single-center, placebo-controlled, triple-blind, superiority clinical trial to assess the prophylactic efficacy and safety of aspirin in patients with ESRD and on hemodialysis. It follows the ethical principles of the Declaration of Helsinki of the World Medical Association. A total of 342 participants would be enrolled over 12 months at a large dialysis center. Patients will be randomized in a 1:1 ratio and stratified by presence of type 2 diabetes mellitus and platelet hyperreactivity to receive either oral aspirin (100 mg/d) or placebo for a treatment period of 12 months. An intention-to-treat statistical analysis will be performed. RESULTS PLEASE WRITE RESULTS. CONCLUSIONS We provide a protocol for a randomized controlled trial to evaluate the safety and efficacy of treatment with aspirin to reduce the risk of thrombotic events. In addition, such a study would further our understanding of the mechanism of aspirin-related bleeding and help identify subgroups of best-responders and patients with a higher risk of adverse events.
- 28 March 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND End-stage renal disease (ESRD) is the last stage of chronic kidney disease, mainly caused by type 2 diabetes mellitus and characterized by an increased mortality risk related to cardiovascular disease. Low-dose aspirin (acetylsalicylic acid or ASA) seems to effectively prevent cardiovascular events in patients with ESRD. However, the number of interventional studies in this population remains limited and the mechanisms of aspirin-related bleeding remain poorly understood. Aspirin’s efficacy and safety may be modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. OBJECTIVE The overall objective of this protocol is to (1) evaluate aspirin’s safety and efficacy in reducing the risk of thrombotic events in patients with ESRD on hemodialysis and (2) examine whether aspirin’s efficacy is modified by the presence of type 2 diabetes mellitus or platelet hyperreactivity. Specifically, the primary objective is to compare the 12-month rate of any thrombotic event (cardiac death, nonfatal myocardial infarction, nonfatal stroke, arteriovenous fistula thrombosis) and Thrombolysis in Myocardial Infarction (TIMI) major bleeding in patients treated with aspirin compared to those on placebo. Secondary objectives are to test for effect modification of treatment by the presence of type 2 diabetes mellitus or platelet hyperreactivity and compare the rate of TIMI minor bleeding between treatment groups. METHODS We developed a protocol for a phase 2 randomized, single-center, placebo-controlled, triple-blind, superiority clinical trial to assess the prophylactic efficacy and safety of aspirin in patients with ESRD and on hemodialysis. It follows the ethical principles of the Declaration of Helsinki of the World Medical Association. A total of 342 participants would be enrolled over 12 months at a large dialysis center. Patients will be randomized in a 1:1 ratio and stratified by presence of type 2 diabetes mellitus and platelet hyperreactivity to receive either oral aspirin (100 mg/d) or placebo for a treatment period of 12 months. An intention-to-treat statistical analysis will be performed. RESULTS PLEASE WRITE RESULTS. CONCLUSIONS We provide a protocol for a randomized controlled trial to evaluate the safety and efficacy of treatment with aspirin to reduce the risk of thrombotic events. In addition, such a study would further our understanding of the mechanism of aspirin-related bleeding and help identify subgroups of best-responders and patients with a higher risk of adverse events.
- Open Access
- 31 March 2006
- Published by Fiocruz - Instituto de Tecnologia em Farmacos in Revista Fitos
- Vol. 1 (03) , 9-17
Comentários sobre o Registro de Fitoterápicos
Phytomedicines are the drugs obtained using exclusively vegetal drug derivates as active constituents, characterized by the knowledge of the effectiveness and the risks of its use, as well as for its quality constancy. Effectiveness and safety can be validated through ethnopharmacological surveys, scientific publications or pre-clinic and clinic pharmacological studies. Safety can also be determined by assays that prove the identity of the plant and the absence of contaminants. The quality must be reached through a control of the raw materials, pharmaceutical formulation, packing materials and stability studies. This article describes some topics of the phytomedicine registration process in the National Health Surveillance Agency (ANVISA), Brazilian agency that regulates and register medicines. Fitoterápico é o medicamento obtido empregando-se exclusivamente derivados de droga vegetal como constituintes ativos, caracterizado pelo conhecimento da eficácia e dos riscos de seu uso, assim como pela constância de sua qualidade. A eficácia e segurança podem ser validadas através de levantamentos etnofarmacológicos de utilização, publicações tecnocientíficas ou estudos farmacológicos e toxicológicos pré-clínicos e clínicos. A segurança também é determinada pelos ensaios que comprovam a identidade da planta e a ausência de contaminantes. A qualidade deve ser alcançada mediante o controle das matérias-primas, do produto acabado, materiais de embalagem, formulação farmacêutica e estudos de estabilidade. Este artigo descreve alguns tópicos do registro de fitoterápicos junto à Agência Nacional de Vigilância Sanitária (ANVISA), órgão brasileiro que regula e registra medicamentos.
- 31 March 2006
- Published by Fiocruz - Instituto de Tecnologia em Farmacos in Revista Fitos
- Vol. 1 (03) , 9-17
Open AccessComentários sobre o Registro de Fitoterápicos
Phytomedicines are the drugs obtained using exclusively vegetal drug derivates as active constituents, characterized by the knowledge of the effectiveness and the risks of its use, as well as for its quality constancy. Effectiveness and safety can be validated through ethnopharmacological surveys, scientific publications or pre-clinic and clinic pharmacological studies. Safety can also be determined by assays that prove the identity of the plant and the absence of contaminants. The quality must be reached through a control of the raw materials, pharmaceutical formulation, packing materials and stability studies. This article describes some topics of the phytomedicine registration process in the National Health Surveillance Agency (ANVISA), Brazilian agency that regulates and register medicines. Fitoterápico é o medicamento obtido empregando-se exclusivamente derivados de droga vegetal como constituintes ativos, caracterizado pelo conhecimento da eficácia e dos riscos de seu uso, assim como pela constância de sua qualidade. A eficácia e segurança podem ser validadas através de levantamentos etnofarmacológicos de utilização, publicações tecnocientíficas ou estudos farmacológicos e toxicológicos pré-clínicos e clínicos. A segurança também é determinada pelos ensaios que comprovam a identidade da planta e a ausência de contaminantes. A qualidade deve ser alcançada mediante o controle das matérias-primas, do produto acabado, materiais de embalagem, formulação farmacêutica e estudos de estabilidade. Este artigo descreve alguns tópicos do registro de fitoterápicos junto à Agência Nacional de Vigilância Sanitária (ANVISA), órgão brasileiro que regula e registra medicamentos.